Currently, there are nine clinical trials registered and evaluating ARX788 in HER2+ breast (NCT01042379) and metastatic breast cancer (NCT04829604 and NCT02512237), HER2-mutated tumors (NCT05041972), HER2-low breast cancer (NCT05018676), breast cancer patients with brain metastasis (NCT05018702), and HER2+ solid tumors (NCT03255070). The gene discussed is ERBB2; the disease is breast cancer.